Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy
We demonstrated a substantial therapeutic efficacy of <sup>177</sup>Lu- and <sup>225</sup>Ac-labeled DOTA-CCK-66. As expected, treatment with the latter resulted in the highest mean survival rates. These results indicate a high therapeutic potential of <sup>225</sup>Ac-labeled DOTA-CCK-66 for TAT in MTC patient management.
Authors
- Clara Diaz Garcia-Prada
- Giuseppe Carlucci (ORCID: https://orcid.org/0000-0001-7494-335X)
- Thomas Günther
- Marco F. Taddio (ORCID: https://orcid.org/0000-0003-2477-5575)
- Christine E. Mona
- Pauline Jeanjean (ORCID: https://orcid.org/0000-0002-7399-3520)
- Nadine Holzleitner (ORCID: https://orcid.org/0000-0001-8258-3526)
- Constantin Lapa (ORCID: https://orcid.org/0000-0001-7536-2207)
- Angela Casini
- Meryl Maria Vilangattil (ORCID: https://orcid.org/0009-0000-8083-8097)
- Abir Swaidan
Institutions
- University of California, Los Angeles (US)
- University of Augsburg (DE)
- Technical University of Munich (DE)
- Stanford University (US)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1007/s00259-024-06927-z
- Citations
- 5
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 2.02
Funders
- Technische Universität München
- Bayerisch-Kalifornischen Hochschulzentrum